- Can you have too many relationships with introducers? (part 1)
- How To Integrate Continuous Improvement Into Your Organization’s Culture And Daily Activities
- Identify The Strengths Of Your Services And Where Improvements Can Be Leveraged
- How To Succeed In A Continually Changing And Unstructured Workplace
- 6 tips to get back in touch with an old colleague
- Paving the Last Mile of Big Data Analytics
- Important Considerations For An Organizational Restructuring
- Elevator Speech 2.0 = Elevator Dialogue
- 4 ways to qualify a lead
- Is the Trusted Advisor Still Trusted?
Accenture: Acquisition of Octagon Research Solutions Completed
September 27, 2012
By Rob Starr, Content Manager, Big4.com
The acquisition of a provider of clinical and regulatory information management solutions and software for the pharmaceutical industry based in Wayne, Pa. has been completed by Accenture. The purchase of Octagon Research Solutions, Inc., enhances Accenture’s existing clinical services capabilities – including clinical data management, clinical programming and safety case processing, among others – and adds regulatory submission services, thereby extending Accenture’s business process outsourcing capabilities for the pharmaceutical industry. As a result, Accenture can now provide the first comprehensive clinical and regulatory services to pharmaceutical companies globally, helping them get medicines to market more quickly and cost effectively.
David Boath, North American managing director for Accenture’s Life Sciences industry group comments:
“Our pharmaceutical clients around the world are looking for proven clinical and regulatory services that can improve the efficiency and effectiveness of their drug development business,” he said. “With Octagon’s deep regulatory expertise and proprietary software – coupled with Accenture’s global delivery network and R&D experience across the in the pharmaceutical industry – we can now offer software-enabled clinical and regulatory services solution from the initial clinical protocol design through to regulatory submission.”